Clinical Trial Update: A Study of Nivolumab Combined With Ipilimumab and Nivolumab Alone in Patients With Advanced or Metastatic Solid Tumors of High Tumor Mutational Burden (TMB-H) [Phase 2]

View source ↗

Summary

Phase 2 trial comparing nivolumab plus ipilimumab vs nivolumab alone in patients with advanced or metastatic solid tumors with high tumor mutational burden (TMB…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• ipilimumab (ipilimumab)
• nivolumab (nivolumab)

Snippet

Sponsor: Bristol-Myers Squibb | Conditions: Pan Tumor | Phase 2 | Status: COMPLETED | Results posted: 2023-05-18